Monte Rosa to Acquire Zura Bio for $1.7B

Ticker: ZURA · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1855644

Zura Bio Ltd 8-K Filing Summary
FieldDetail
CompanyZura Bio Ltd (ZURA)
Form Type8-K
Filed DateJan 13, 2025
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentbullish

Sentiment: bullish

Topics: acquisition, biotech, merger

Related Tickers: MTSR, ZURA

TL;DR

Monte Rosa is buying Zura Bio for $1.7B cash, $40/share. Deal closes Q1 2025.

AI Summary

Zura Bio Ltd. announced on January 13, 2025, that it has entered into a definitive agreement to be acquired by Monte Rosa Therapeutics, Inc. The transaction is valued at approximately $1.7 billion, with Zura Bio shareholders set to receive $40.00 per share in cash. This acquisition aims to combine Zura Bio's pipeline with Monte Rosa's expertise in targeted protein degradation.

Why It Matters

This acquisition represents a significant consolidation in the biotechnology sector, potentially impacting the development of new therapies for various diseases.

Risk Assessment

Risk Level: medium — The acquisition is subject to customary closing conditions, including regulatory approvals and shareholder consent, which introduce a degree of uncertainty.

Key Numbers

  • $1.7B — Acquisition Value (Total value of the transaction between Monte Rosa Therapeutics and Zura Bio Ltd.)
  • $40.00 — Per Share Price (Cash amount to be received by Zura Bio shareholders for each share.)

Key Players & Entities

  • Zura Bio Ltd. (company) — Registrant
  • Monte Rosa Therapeutics, Inc. (company) — Acquiring company
  • $1.7 billion (dollar_amount) — Acquisition valuation
  • $40.00 per share (dollar_amount) — Per share acquisition price
  • January 13, 2025 (date) — Date of report

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing reports on the definitive agreement for Monte Rosa Therapeutics, Inc. to acquire Zura Bio Ltd.

What is the total value of the acquisition?

The acquisition is valued at approximately $1.7 billion.

How much will Zura Bio shareholders receive per share?

Zura Bio shareholders will receive $40.00 in cash per share.

Who is acquiring Zura Bio Ltd.?

Zura Bio Ltd. is being acquired by Monte Rosa Therapeutics, Inc.

When is the expected closing date for the acquisition?

The filing does not specify an exact closing date but indicates it is subject to customary closing conditions, implying it will occur after regulatory and shareholder approvals.

Filing Stats: 551 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2025-01-13 06:45:39

Key Financial Figures

  • $0.0001 — ed Class A Ordinary Shares, par value $0.0001 per share ZURA The Nasdaq Stock Mar

Filing Documents

01

Item 7.01. Regulation FD Disclosure. On January 13, 2025, Zura Bio Limited (" ZURA ", the " Company ") provided an updated corporate presentation that may be used in connection with presentations at conferences and investor meetings. The full text of the Company's corporate presentation is filed as Exhibit 99.1 hereto, and incorporated herein by reference, and may also be accessed through the "News & Events" section of the Company's website at investors.zurabio.com. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, or in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Corporate Presentation, dated January 13, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZURA BIO LIMITED Date: January 13, 2025 By: /s/ Kim Davis Kim Davis Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.